With Intuniv (guanfacine), a new type of non-stimulant ADHD medication is introduced. Intuniv is approved for the treatment of ADHD in children and adolescents when central nervous stimulants are not suitable, not tolerated or have no effect. Thus, Intuniv has a more restrictive indication compared to the other non-stimulant ADHD medicine, atomoxetine.
Compared to placebo, Intuniv has an effect on ADHD core symptoms with medium effect size. It suggests that the effect of Intuniv is lower than that of methylphenidate, but comparable to or higher than that of atomoxetine. No convincing effect on functioning has been established.
Adverse reactions and risks of interactions are significant and may be serious; especially sedation and somnolence are common and influence Intuniv's effect on ADHD core symptoms. Intuniv affects heart rate and blood pressure, and incidents of syncope have been reported.
It is IRF's overall assessment that Intuniv, like dexamfetamine, should only be used in ADHD treatment if methylphenidate, atomoxetine and lisdexamfetamine are not suitable, not tolerated or have no effect, because the profile of adverse drug reactions and the risk of interactions give cause for concern.